ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(4 sites)
United States
University of Chicago Comprehensive Cancer Center, Chicago, Illinois Dana Farber Cancer Institute, Boston, Massachusetts Beth Israel Deaconess Medical Center, Boston, Massachusetts Roswell Park Comprehensive Cancer Center, Buffalo, New York Last updated November 2025